Genmab Announces Preliminary Safety and Efficacy Data for Daratumumab
Genmab A/S
11.12.2011 02:28
Dissemination of a Adhoc News, transmitted by DGAP - a company of
EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
- Preliminary Phase I/II data show daratumumab is active in multiple myeloma &
has an acceptable safety profile
- Data presented in poster session today at the ASH Annual Meeting
Copenhagen, Denmark; December 11, 2011 - Genmab A/S (OMX: GEN) announced today
encouraging preliminary safety and efficacy data from the first Phase I/II
clinical study of daratumumab (HuMax(r)-CD38) in multiple myeloma. A 49%, 55%,
and 61% reduction in the serum M-component was observed in the three patients
treated at the highest dose level examined so far (4 mg/kg of daratumumab).
The serum M-component is an abnormal protein produced by the cancerous plasma
cells and is a direct marker for tumor activity. Reduction in the serum
M-component is a key factor for response evaluations in multiple myeloma. The
observed level of reduction therefore indicates that daratumumab was clinically
active in these multiple myeloma patients.
The data presented today was from 23 patients who received daratumumab in doses
up to 4mg/kg. The data also showed daratumumab has an acceptable safety
profile. The most common adverse events seen in the study so far were pyrexia,
cough, free hemoglobin, anemia, dizziness, hemolysis, flu-like illness, nausea,
lymphopenia and monocytopenia.
'We are delighted to share these preliminary data which offer the first insight
we have into the activity of daratumumab in multiple myeloma. We have not yet
reached the maximum tolerated dose and therefore the study will continue to
examine patients at higher doses and we look forward to announcing detailed
safety and response data at a later date,' said Jan van de Winkel, Ph.D., Chief
Executive Officer of Genmab.
The poster presented at ASH today can be accessed at Genmab's website
www.genmab.com.
About the study
This ongoing Phase I/II dose escalation study will include a maximum of 122
patients with multiple myeloma that is relapsed or refractory to at least two
different prior treatments. The primary objective of the study is to establish
the safety profile of daratumumab and secondary objectives are to establish
maximum tolerated dose and efficacy. An independent data monitoring committee
evaluates the safety data for each cohort before dose-escalation. For more
detailed information on the study including the dosing cohorts, please see the
poster presented at ASH, posted on Genmab's website.
About daratumumab
Daratumumab is a human CD38 monoclonal antibody with broad-spectrum killing
activity. Daratumumab is in clinical development for multiple myeloma. The
CD38 molecule is highly expressed on the surface of multiple myeloma cells.
CD38 is also expressed on a number of other hematological tumors, including
diffuse large B-cell lymphoma, chronic lymphocytic leukemia, acute
lymphoblastic leukemia, acute myeloid leukemia, follicular lymphoma and mantle
cell lymphoma.
About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company's first marketed
antibody, Arzerra(r) (ofatumumab), was approved to treat chronic lymphocytic
leukemia that is refractory to fludarabine and alemtuzumab after less than
eight years in development. Genmab's validated and next generation antibody
technologies are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and technologies is a
key focus of Genmab's strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communication
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com
This Company Announcement contains forward looking statements. The words
'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab's most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.
Genmab(r); the Y-shaped Genmab logo(r); HuMax(r); HuMax-CD20(r); HuMax(r)-EGFr;
HuMax(r)-IL8; HuMax(r)-TAC; HuMax(r)-CD38; HuMax(r)-TF; HuMax(r)-Her2; HuMax(r)-cMet,
HuMax(r)-CD74, DuoBody(tm) and UniBody(r) are all trademarks of Genmab A/S. Arzerra(r)
is a trademark of GlaxoSmithKline.
Company Announcement no. 35
CVR no. 2102 3884
Genmab A/S
Bredgade 34
1260 Copenhagen K
Denmark
Click on, or paste the following link into your web browser, to view the associated documents
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=371582
News Source: NASDAQ OMX
11.12.2011 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Genmab A/S
DÀnemark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Genmab A/S
11.12.2011 02:28
Dissemination of a Adhoc News, transmitted by DGAP - a company of
EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
- Preliminary Phase I/II data show daratumumab is active in multiple myeloma &
has an acceptable safety profile
- Data presented in poster session today at the ASH Annual Meeting
Copenhagen, Denmark; December 11, 2011 - Genmab A/S (OMX: GEN) announced today
encouraging preliminary safety and efficacy data from the first Phase I/II
clinical study of daratumumab (HuMax(r)-CD38) in multiple myeloma. A 49%, 55%,
and 61% reduction in the serum M-component was observed in the three patients
treated at the highest dose level examined so far (4 mg/kg of daratumumab).
The serum M-component is an abnormal protein produced by the cancerous plasma
cells and is a direct marker for tumor activity. Reduction in the serum
M-component is a key factor for response evaluations in multiple myeloma. The
observed level of reduction therefore indicates that daratumumab was clinically
active in these multiple myeloma patients.
The data presented today was from 23 patients who received daratumumab in doses
up to 4mg/kg. The data also showed daratumumab has an acceptable safety
profile. The most common adverse events seen in the study so far were pyrexia,
cough, free hemoglobin, anemia, dizziness, hemolysis, flu-like illness, nausea,
lymphopenia and monocytopenia.
'We are delighted to share these preliminary data which offer the first insight
we have into the activity of daratumumab in multiple myeloma. We have not yet
reached the maximum tolerated dose and therefore the study will continue to
examine patients at higher doses and we look forward to announcing detailed
safety and response data at a later date,' said Jan van de Winkel, Ph.D., Chief
Executive Officer of Genmab.
The poster presented at ASH today can be accessed at Genmab's website
www.genmab.com.
About the study
This ongoing Phase I/II dose escalation study will include a maximum of 122
patients with multiple myeloma that is relapsed or refractory to at least two
different prior treatments. The primary objective of the study is to establish
the safety profile of daratumumab and secondary objectives are to establish
maximum tolerated dose and efficacy. An independent data monitoring committee
evaluates the safety data for each cohort before dose-escalation. For more
detailed information on the study including the dosing cohorts, please see the
poster presented at ASH, posted on Genmab's website.
About daratumumab
Daratumumab is a human CD38 monoclonal antibody with broad-spectrum killing
activity. Daratumumab is in clinical development for multiple myeloma. The
CD38 molecule is highly expressed on the surface of multiple myeloma cells.
CD38 is also expressed on a number of other hematological tumors, including
diffuse large B-cell lymphoma, chronic lymphocytic leukemia, acute
lymphoblastic leukemia, acute myeloid leukemia, follicular lymphoma and mantle
cell lymphoma.
About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company's first marketed
antibody, Arzerra(r) (ofatumumab), was approved to treat chronic lymphocytic
leukemia that is refractory to fludarabine and alemtuzumab after less than
eight years in development. Genmab's validated and next generation antibody
technologies are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and technologies is a
key focus of Genmab's strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communication
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com
This Company Announcement contains forward looking statements. The words
'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab's most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.
Genmab(r); the Y-shaped Genmab logo(r); HuMax(r); HuMax-CD20(r); HuMax(r)-EGFr;
HuMax(r)-IL8; HuMax(r)-TAC; HuMax(r)-CD38; HuMax(r)-TF; HuMax(r)-Her2; HuMax(r)-cMet,
HuMax(r)-CD74, DuoBody(tm) and UniBody(r) are all trademarks of Genmab A/S. Arzerra(r)
is a trademark of GlaxoSmithKline.
Company Announcement no. 35
CVR no. 2102 3884
Genmab A/S
Bredgade 34
1260 Copenhagen K
Denmark
Click on, or paste the following link into your web browser, to view the associated documents
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=371582
News Source: NASDAQ OMX
11.12.2011 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Genmab A/S
DÀnemark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------